Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study

Svetomir N. Markovic, Filippo Galli, Vera J. Suman, Wendy K. Nevala, Andrew Paulsen, Joseph C. Hung, Denise N. Gansen, Lori A. Erickson, Paolo Marchetti, Gregory A. Wiseman,

Oncotarget · 2018 · 60 citations · 20 references

DOIFull text

Open access

Concepts

Abstract

// Svetomir N. Markovic 1, 4 , Filippo Galli 2 , Vera J. Suman 3 , Wendy K. Nevala 4 , Andrew M. Paulsen 5 , Joseph C. Hung 5 , Denise N. Gansen 5 , Lori A. Erickson 6 , Paolo Marchetti 7 , Gregory A. Wiseman 5 and Alberto Signore 2 1 Department of Oncology, Mayo Clinic, Rochester, MN, USA 2 Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, “Sapienza” University of Rome, Rome, Italy 3 Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA 4 Department of Immunology, Mayo Clinic, Rochester, MN, USA 5 Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA 6 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA 7 Oncology Unit, Department of Clinical and Molecular Medicine, “Sapienza” University of Rome, and IDI-IRCCS, Rome, Italy Correspondence to: Alberto Signore, email: alberto.signore@uniroma1.it Keywords: check point inhibitors; ipilimumab; pembrolizumab; melanoma; 99m Tc-IL2 Received: December 28, 2017      Accepted: June 04, 2018      Published: July 13, 2018 ABSTRACT Early in the course of immunotherapy there is frequently a transient enlargement of tumor masses (pseudo-progression) due to tumor infiltration by TILs. Current clinical imaging modalities are not able to distinguished pseudo-progression from true tumor progression. Thus, patients often remain on treatment 4-8 weeks longer to confirm disease progression. Nuclear medicine offers the possibility to image immune cells and potentially discriminate pseudo-progression and progression. We conducted a pilot study in patients with metastatic melanoma receiving ipilimumab (IPI) or pembrolizumab (PEMBRO) to assess safety and feasibility of SPECT/CT imaging with 99m Tc- interleukin-2 ( 99m Tc-HYNIC-IL2) to detect TILs and distinguish between true progression from pseudo- progression. Scans were performed prior to and after 12w treatment. After labelling, 99m Tc-HYNIC-IL2 was purified and diluted in 10 mL of 5% glucose with 0.1% human serum albumin. Of the 5 patients (2 treated with IPI and 3 with PEMBRO) enrolled, two failed to complete the second scan as they discontinued IPI due grade 3 colitis (1 patient) or patient refusal after developing multiple toxicities attributed to IPI (1 patient). Following the first scan, one patient reported to have a grade 1 pruritus with grade 1 pain. No other toxicities attributed to the radiopharmaceutical infusion were reported. Metastatic lesions could be visualized by 99m Tc-IL2 imaging and there was positive correlation between size and 99m Tc-HYNIC-IL2 uptake, both before and after 12 weeks of therapy. The results of this pilot study demonstrate the safety and feasibility of 99m Tc-IL2 imaging and has led to a number of hypotheses to be tested in future studies.

References

20